Cardiac and vascular therapy developer Guidant has received FDA approval for its Galileao intravascular radiotherapy system for the treatment of coronary artery disease. The system is already available in Europe, Guidant said.
Galileo III's enhanced automation features will make it easier for physicians to treat in-stent restenosis with intravascular radiotherapy, according to Guidant's president of vascular intervention, John M. Capek, Ph.D.
In particular, the system's AutoStep technology is designed to facilitate the treatment of long lesions by delivering radiation therapy starting at the distal end of the blockage, automatically stepping the radiation treatment through a catheter to treat the length of the artery needing therapy, the company said.
In a trail conducted by Guidant, the system demonstrated a 71% reduction in binary restenosis and a 47 percent reduction in the incidence of Major Adverse Cardiac Events (MACE), according to the firm.
By AuntMinnie.com staff writersSeptember 24, 2002
Related Reading
Cook gets OK to test new vascular stent, August 16, 2002
Guidant to buy Cook, July 30, 2002
Copyright © 2002 AuntMinnie.com
